Siemens Fonds Invest GmbH Sells 10,839 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Siemens Fonds Invest GmbH reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 82.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,301 shares of the medical research company's stock after selling 10,839 shares during the quarter. Siemens Fonds Invest GmbH's holdings in Thermo Fisher Scientific were worth $1,197,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in TMO. Stonegate Investment Group LLC grew its holdings in shares of Thermo Fisher Scientific by 0.3% in the fourth quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock valued at $3,531,000 after purchasing an additional 18 shares during the period. Semus Wealth Partners LLC boosted its holdings in Thermo Fisher Scientific by 4.0% in the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock valued at $245,000 after purchasing an additional 18 shares during the last quarter. Eagle Rock Investment Company LLC increased its holdings in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Eagle Rock Investment Company LLC now owns 7,463 shares of the medical research company's stock worth $3,882,000 after buying an additional 19 shares during the last quarter. KRS Capital Management LLC raised its position in shares of Thermo Fisher Scientific by 1.5% during the 4th quarter. KRS Capital Management LLC now owns 1,317 shares of the medical research company's stock valued at $685,000 after buying an additional 20 shares during the period. Finally, Revolve Wealth Partners LLC grew its position in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after acquiring an additional 20 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. The trade was a 25.87% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,075 shares of company stock worth $7,305,942. 0.33% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on TMO. Argus decreased their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. UBS Group decreased their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Finally, Citigroup reduced their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $607.43.

Thermo Fisher Scientific Price Performance

TMO stock opened at $412.15 on Friday. The business has a 50 day simple moving average of $453.88 and a 200-day simple moving average of $510.42. The company has a market capitalization of $155.58 billion, a P/E ratio of 24.93, a PEG ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a twelve month low of $390.50 and a twelve month high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same period last year, the firm posted $5.11 EPS. Thermo Fisher Scientific's revenue for the quarter was up .2% on a year-over-year basis. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.